Navigation Links
Boston Scientific Agrees to Sell Neurovascular Business to Stryker
Date:10/28/2010

oking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; closing of announced divestures and related transitions; our restructuring initiatives; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific Corporation
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... June 30, 2015 , ... In the Spring of 2015, ... in the Sierra Nevada mountains measured zero for the first time since records have ... of one of its most sustained periods of increasing drought.” , In ...
(Date:6/30/2015)... ... ... America is in a health crisis. Today, 4 out of 5 Americans will ... The answer is simple and is at the core of every disease and dysfunction—stress. ... one million patients and, for the first time ever, gives readers and followers 12 ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reliable source for ... Stadium in Provo, Utah. This legendary band has been packing venues for years and ... have also released more than 20 albums in their career. While Journey is known ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... article, early humans who lived three to four hundred thousand years ago likely ... health. By examining the chemical compounds in fossilized, ancient dental plaque, researchers were able ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier ... own Debby Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored ... Recognition Award for her contribution to the RBMA Coding Subcommittee. , Ms. ...
Breaking Medicine News(10 mins):Health News:RainSoil launches water-retention product as drought spreads. 2Health News:RainSoil launches water-retention product as drought spreads. 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2
... research has found that travelers who are prone to ... risk by pulling on a pair of elastic support ... the evidence that compression stockings can prevent deep vein ... condition in which blood coagulates into small clots inside ...
... outcome, when a nurse, nurses an urge to kill. ... profession, was convicted of murdering two patients // and ... General Hospital in Oxfordshire. ,The accused had injected ... caused the patients’ to stop breathing.Geen had committed these ...
... high time somebody spoke of retirement blues. A study ... retirement despondency claims three important factors that measure a ... outlook physical health and pension, in that order. Surprisingly, ... list for a happy retirement. ,The study tracked ...
... Concerns have been raised about the alarming rate of ... According to official estimates, about 6% of Australian children ... ,VicHealth, one of the important health promotion bodies of ... to curb childhood obesity. Additionally, it has pointed out ...
... who develop pre-eclampsia, which are a condition of abnormally high ... a stroke during pregnancy. // But new studies by ... and Prevention now report that pre-eclampsia is also a risk ... Brown and colleagues in Atlanta used data from the Stroke ...
... is better than Tamoxifen in preventing breast cancer in ... said that both drugs reduce the risk of cancer ... trial show that Eli Lilly and Co's Evista, known ... could prompt clinicians to replace Tamoxifen with Evista in ...
Cached Medicine News:Health News:Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings 2
... The Apollo Knee System has been ... through range of motion of any fixed ... area and low contact stress under loading ... contributes to long-term effectiveness. The universal symmetrical ...
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
The AGC dual articular knee is indicated for severe primary or revision cases and features a patented unique articulation which allows controlled rotation of the femoral component about a central piv...
... NexGen CRA femoral component is intended ... anteroposterior, and varus/valgus ligament stability, yet ... to inadequate bone stock. The NexGen ... a PMMA precoat surface. This device ...
Medicine Products: